A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of ONO-2333Ms in patients with recurrent major depressive disorder.
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2012
At a glance
- Drugs ONO 2333Ms (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 21 Oct 2011 Actual end date changed from Apr 2008 to Jun 2008 as reported by ClinicalTrials.gov.
- 12 Nov 2008 Updated end date and actual patient number as reported in ClinicalTrials.gov record.
- 12 Nov 2008 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.